Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry
Table 3
Postprocedural data of Croatian CRT population and comparison with the European average.
Croatia
Europe
value
OR (95% CI)
Hospital mortality
0.9 (1/111)
0.4 (44/10734)
0.409
Device-related complications
Lead displacement
2.7 (3/110)
1.7 (185/10720)
0.424
RV
0.0 (0/3)
31.6 (55/174)
0.241
LV
66.7 (2/3)
52.3 (91/174)
0.621
Atrial
33.3 (1/3)
19.0 (33/174)
0.531
Lead malfunction
0.0 (0/110)
0.2 (23/10720)
0.627
Phrenic nerve stimulation
1.8 (2/110)
1.1 (121/10720)
0.497
Infection
0.0 (0/110)
0.6 (60/10706)
0.431
Stroke
0.0 (0/110)
0.1 (6/10706)
0.804
Worsening of HF
0.0 (0/110)
0.7 (78/10706)
0.369
Arrhythmias
0.9 (1/110)
1.2 (127/10706)
0.789
Total length of hospital stay
6.8 ± 7.5
6.3 ± 11.4
0.002
Mean-paced QRS duration (ms)
113 ± 19
138 ± 24
<0.001
Medical therapy at discharge
Diuretic
89.1 (98/110)
81.0 (8523/10525)
0.031
1.92 (1.05–3.50)
ACE inhibitor/ARB
84.1 (90/107)
86.4 (9073/10496)
0.484
Aldosterone antagonist
71.8 (79/110)
63.1 (6603/10463)
0.059
Beta blocker
94.5 (104/110)
88.9 (9368/10538)
0.06
Digoxin
5.6 (6/107)
10.5 (1094/10437)
0.101
Calcium channel blocker
6.7 (7/105)
9.0 (939/10426)
0.404
Amiodarone
35.5 (38/107)
17.1 (1787/10440)
<0.001
2.67 (1.79–3.98)
Ivabradine
0.0 (0/108)
5.7 (593/10435)
0.011
/
Other antiarrhythmic agents
1.9 (2/108)
1.7 (179/10423)
0.256
Oral anticoagulant
46.4 (51/110)
46.6 (4877/10467)
0.962
Vitamin K antagonist
86.3 (44/51)
70.1 (3419/4877)
0.012
2.68 (1.20–5.96)
Dabigatran
3.9 (2/51)
6.7 (325/4877)
0.434
Rivaroxaban
3.9 (2/51)
12.5 (609/4877)
0.065
Apixaban
5.9 (3/51)
10.4 (506/4877)
0.294
Edoxaban
0.0 (0/51)
0.4 (18/4877)
0.664
Platelet inhibitor
25.2 (29/115)
43.9 (4817/10973)
<0.001
0.43 (0.28–0.66)
ASA
24.8 (27/109)
41.5 (4330/10438)
<0.001
0.46 (0.30–0.72)
Clopidogrel
6.4 (7/109)
12.4 (1297/10438)
0.058
0.48 (0.22–1.04)
Ticagrelor
0.9 (1/109)
1.3 (135/10438)
0.729
0.71 (0.10–5.10)
Dual antiplatelet therapy
5.5 (6/109)
9.3 (975/10438)
0.17
OAC plus P2Y12 inhibitor
1.8 (2/110)
4.2 (438/10510)
0.219
Triple therapy
1.8 (2/110)
2.1 (216/10511)
0.862
Device follow-up planned
95.7 (110/115)
97.6 (10708/10973)
0.181
0.54 (0.22–1.35)
At implanting centre
100.0 (110/110)
86.2 (9235/10708)
<0.001
Values are % () for categorical and mean ± standard deviation or median (25th–75th percentile) for continuous variables. RV: right ventricle; LV: left ventricle; ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker; ASA: acetylsalicylic acid; OAC: oral anticoagulation.
